BSD Medical Corporation to Begin Trading on Amex as BSM
June 09 2005 - 6:00AM
PR Newswire (US)
BSD Medical Corporation to Begin Trading on Amex as BSM SALT LAKE
CITY, June 9 /PRNewswire-FirstCall/ -- BSD Medical Corporation
(AMEX:BSM) today announced that the company will begin trading on
the American Stock Exchange (Amex) on Thursday, June 9th, using the
symbol BSM. Those who have previously traded BSD Medical's shares
under the bulletin board symbol BSDM should begin to trade using
the Amex symbol BSM beginning Thursday morning, June 9th. "We
believe that listing on the American Stock Exchange, as opposed to
the bulletin board, will help increase the visibility of BSD
Medical on Wall Street, and provide additional trading liquidity
for investors," according to Hyrum A. Mead, President of BSD
Medical Corporation. "This is another important step in our
strategic efforts on behalf of the company." This approval is
contingent upon the Company being in compliance with all applicable
listing standards on the date it begins trading on the Exchange,
and may be rescinded if the Company is not in compliance with such
standards. About BSD Medical Corporation BSD Medical develops,
manufactures, markets and services systems that deliver focused
RF/microwave energy to raise temperatures within diseased sites in
the body as required by a variety of medical therapies. BSD
pioneered the use of microwave thermal therapy for the treatment of
enlarged prostate symptoms (BPH), and is responsible for much of
the technology that has created a substantial medical industry
based on that therapy. BSD's primary thrust is in the
commercialization of systems used for the treatment of cancer, and
in developments to treat other diseases and medical conditions. BSD
was the recent recipient of the Frost and Sullivan "Technology of
the Year Award" for cancer therapy devices. For further information
visit the BSD website at http://www.bsdmc.com/. Statements
contained in this press release that are not historical facts are
forward-looking statements, as that item is defined in the Private
Securities Litigation Reform Act of 1995. All forward-looking
statements, including all projections and expectations of future
events, such as current expectations for the successful
commercialization of developments for the treatment of cancer and
other diseases and conditions and the future price or liquidity of
the stock based on the Amex listing, are subject to risks and
uncertainties, some of which are detailed in part in the Company's
filings with the Securities and Exchange Commission. DATASOURCE:
BSD Medical Corporation CONTACT: Hyrum A. Mead of BSD Medical
Corporation, +1-801-972-5555, fax +1-801-972-5930, Web site:
http://www.bsdmc.com/
Copyright